MedTrace Logo

Antibiotic Therapy for Infectious Diseases

NCT04937894 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-06-24

No results posted yet for this study

Summary

Tigecycline is a last-resort antibiotic that is used to treat severe infections caused by extensively drug-resistant bacteria. However, the efficacy and safety data for tigecycline in infectious patients are lacking. The aim of this study is to assess the efficacy and safety of tigecycline in infectious patients using pharmacokinetics and omics.

Conditions

Interventions

DRUG

Tigecycline

Efficacy and safety of Tigecycline

Sponsors & Collaborators

  • Shandong Provincial Hospital

    collaborator OTHER_GOV

  • Shandong University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2025-07-01
Completion
2025-12-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04937894 on ClinicalTrials.gov